Scrip

Emergent Broadens Bioterror Offering In $125m Sanofi Smallpox Vaccine Buy

17 Jul 2017

• By Sten Stovall

Sanofi's divestment of its ACAM200 smallpox vaccine frees it to focus on "current and emerging" infectious disease jabs - while expanding Emergent BioSolutions adds to its anti-bioterror product offering.

Emergent BioSolutions Inc. - one of the vaccine producers that the US federal government relies on for its bioterror preparedness – is expanding its product offering by buying Sanofi's ACAM2000 smallpox vaccine, in a deal valued at up to $125m.

The all-cash transaction consists of $97.5m paid upfront to Emergent BioSolutions and up to $27.5m in near-term contingent...